BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Basilea Pharmaceutica 

Grenzacherstrasse 487

Basel    CH-4005  Switzerland
Phone: 41-61-6061-111 Fax: 41-61-6061-112


SEARCH JOBS








 Company News
Basilea Pharmaceutica (BSLN.SW) Reports Presentation of New Data on Anti-Infective Drug Candidates Addressing Drug Resistance 4/29/2013 12:24:12 PM    More...
Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica (BSLN.SW) 4/9/2013 12:15:07 PM    More...
Basilea Pharmaceutica (BSLN.SW)'s Board Proposes Martin Nicklasson to Succeed Chairman Werner Henrich and Recommends to Shareholders That They do Not Support the Request for a Capital Distribution at This Time 3/7/2013 9:49:43 AM    More...
Basilea Pharmaceutica (BSLN.SW) Receives Request to Place Repayment of CHF 48 Million From Capital Contribution Reserve on the Agenda of the Ordinary General Meeting of Shareholders 2/26/2013 9:14:42 AM    More...
Basilea Pharmaceutica (BSLN.SW) Reports Recruitment Completion of Phase 3 Pivotal Study of Isavuconazole, an Agent for the Potential Primary Treatment of Invasive and Life-Threatening Fungal Infections 12/14/2012 9:56:26 AM    More...
Basilea Pharmaceutica (BSLN.SW) Promotes Ronald Scott to CEO, Replacing Anthony Man 12/10/2012 7:40:15 AM    More...
Basilea Pharmaceutica (BSLN.SW) Initiates Next Phase 1 Multiple Ascending Dose Study With Antibiotic Bal30072 Active Against Multidrug-Resistant Gram-Negative Bacteria 11/26/2012 11:55:46 AM    More...
Basilea Pharmaceutica (BSLN.SW)'s Novel Oncology Drug Candidate BAL101553: Data Presented at International Conference Demonstrate Dual Mode of Action 11/6/2012 7:16:12 AM    More...
Basilea Pharmaceutica (BSLN.SW)'s European Marketing Authorization Application for ceftobiprole for the Treatment of Pneumonia Accepted for Review 10/5/2012 9:35:18 AM    More...
Basilea Pharmaceutica (BSLN.SW) Reports Presentation of New Data on Investigational Anti-Infectives Isavuconazole, Ceftobiprole and BAL30072 at ICAAC 9/12/2012 10:04:25 AM    More...
12345678910...